Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 8-K

ACURA PHARMACEUTICALS, INC Form 8-K November 02, 2007

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934

November 2, 2007

Date of Report (Date of earliest event reported)

ACURA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

State of New York (State of Other Jurisdiction of Incorporation) 1-10113

(Commission File Number)

11-0853640

(I.R.S. Employer Identification Number)

616 N. North Court, Suite 120 Palatine, Illinois 60067

(Address of principal executive offices) (Zip Code)

(847) 705-7709

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 8-K

Item 2.02 Results of Operations and Financial Condition

On November 2, 2007, the Registrant issued a press release disclosing the financial results for its third quarter ended September 30, 2007. A copy of the Registrant's press release is attached as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits

Exhibit Number	Description
99.1	Press Release dated November 2, 2007 Announcing Financial Results for the Third Quarter of 2007

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ACURA PHARMACEUTICALS, INC.

By: /s/ Peter A.

Clemens
Peter A.
Clemens
Senior Vice
President &
Chief Financial

Officer

Date: November 2, 2007

Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 8-K

Exhibit Index

Exhibit Number	Description
99.1	Press Release dated November 2, 2007 Announcing Financial Results for the Third Quarter of 2007